drugset
Drugs / Zalutumumab
last change Nov 2016 re-read 3 minutes ago

Zalutumumab

also known as HuMax-EGFr · HUMAX-EGFR, 2F8

Monoclonal antibody targets EGFR

Developed for
head and neck cancer · squamous cell carcinoma · non-small cell lung carcinoma · colorectal cancer · head and neck squamous cell carcinoma
Investigated by
Genmab · Danish Head and Neck Cancer Group

Trials 9

today NCT01054625 · Ph 1/2 NCT00707655 · Ph 1/2 NCT00677924 · Ph 1/2 NCT00542308 · Ph 2 NCT00496652 · Ph 3 NCT00460551 · Ph 2 NCT00401401 · Ph 1/2 NCT00093041 · Ph 1/2
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/25 trials
Phase 1/2 NCT01054625 Mar 2010 → Jul 2011 head and neck cancer Genmab Completed No outcome recorded
Phase 1/2 NCT00707655 Sep 2008 → Oct 2010 head and neck cancer, squamous cell carcinoma Genmab Terminated No outcome recorded
Phase 1/2 NCT00677924 Apr 2008 → Apr 2009 colorectal cancer Genmab Terminated No outcome recorded Stop: Business
Phase 1/2 NCT00401401 Dec 2006 → Oct 2010 head and neck cancer, squamous cell carcinoma Genmab Terminated No outcome recorded
Phase 1/2 NCT00093041 Dec 2003 → Jan 2005 head and neck squamous cell carcinoma Genmab Completed No outcome recorded
Phase 23 trials
Phase 2 NCT00542308 Jan 2008 → Aug 2011 head and neck cancer, squamous cell carcinoma Genmab Completed No outcome recorded
Phase 2 NCT00460551 Apr 2007 → Oct 2008 non-small cell lung carcinoma Genmab Terminated No outcome recorded
Phase 2 NCT01449357 — non-small cell lung carcinoma Genmab Withdrawn No outcome recorded
Phase 31 trial · 1 missed
Phase 3 NCT00496652 Nov 2007 → Jul 2012 head and neck cancer Danish Head and Neck Cancer Group Completed Missed primary
Comparator or background therapy1 trial
Phase 3 NCT00382031 Comparator Nov 2006 → Dec 2009 head and neck squamous cell carcinoma Genmab Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as zalutumumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT00401401 ↗
9

NCT00707655 ↗

NCT00496652 ↗

NCT00460551 ↗

NCT01449357 ↗

NCT01054625 ↗

NCT00382031 ↗

NCT00093041 ↗

NCT00542308 ↗

NCT00677924 ↗
Known as HuMax-EGFr ChEMBL registry synonym — accepted as the source's own label CHEMBL2107861 ↗
Known as HUMAX-EGFR, 2F8 ChEMBL registry synonym — accepted as the source's own label CHEMBL2107861 ↗
Action Inhibit “EGFR inhibitor zalutumumab” NCT00496652 ↗
Modality Monoclonal antibody “monoclonal antibody against EGFr” PMID 17602769 ↗ Jun 2007
Route Intravenous “Individual dose titration weekly i.v doses” NCT00382031 ↗
Target EGFR “a human IgG1 monoclonal antibody targeting the epidermal growth factor receptor” PMID 21377930 ↗ Mar 2011